FDAsafety guidance83% confidence
S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to pridopidine.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Neurology · ALS
- Sub-indication
- General
Related signal: Pridopidine Phase 3 Trial Initiated for ALS Efficacy and Safety Evaluation
Source
FDA document
View source